Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Clover

Fiserv Targets ‘Constant Compounder’ Comeback as Clover, AI and Banking Bets Ramp

Fiserv (NASDAQ:FISV) Chief Executive Officer Mike Lyons said the payments and financial technology company is focused on returning to a “constant compounder” profile by sharpening its business mix, improving execution and investing around two major markets: banking and commerce. Speaking with J.P.

MarketBeat

Fiserv Investor Day Sets AI, Clover Roadmap to Revive Growth and Top $12 EPS

Fiserv (NASDAQ:FISV) executives used the company’s 2026 Investor Day to outline a medium-term plan aimed at restoring what CEO Mike Lyons described as Fiserv’s historical identity as a “constant compounder,” while acknowledging recent service, product delivery and client retention challenges. Lyons

MarketBeat

Ally Voss, Founder of Clover London, Shares a Glimpse Into Her 9-5

The brains behind the contemporary bridal brand lifts the lid on her stylish world

Marie Claire

From analysis to the latest developments in health,
read the most diverse news in one place.

How to Select The Best Card Machine for Your Customer Needs

Selecting the right card machine is crucial for businesses aiming to provide seamless payment experiences. With numerous options available, it's essential to understand your specific needs to make an informed choice.

inkl

"The failure of Scalebound was ultimately the responsibility of PlatinumGames, myself as director included"— Hideki Kamiya, creator of Devil May Cry and Okami, takes responsibility for Scalebound's cancellation

VGA recently interviewed Hideki Kamiya and Kento Koyama, the heads of the young studio CLOVERS, regarding its formation and the cancellation of Scalebound.

Windows Central

Clover Beats Q2 Estimates, Stock Drops: Here Are The Details

Healthcare technology company Clover Health Investments Corp. (NASDAQ:CLOV) is trading lower after reporting second-quarter financial results after market close on Tuesday.

Benzinga

What's Going On With Clover Health Stock?

Clover Health Investments, Corp. (NASDAQ:CLOV) stock is trading 5% higher on Tuesday, adding to gains of more than 12% over the past week. Here’s a look at some key highlights.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

MarketBeat

“People think we’re a pop band. But we never have been. We just had some huge success that hurt us a little”: how Huey Lewis & The News became America’s favourite good time rock’n’roll band

Huey Lewis & The News were the ultimate bar-room rockers made good – all it took was a little nudge from Mutt Lange and Michael J Fox

Louder

4-H teams with Netflix's 'Spy Kids: Armageddon' to launch new learning platform Clover

The National 4-H Council is growing in a new direction – online – by launching its e-learning platform Clover with a collaboration with Netflix and its new movie “Spy Kids: Armageddon.”

The Independent UK

Clover Health Investments (CLOV): Buy, Hold or Sell End of June?

Clover Health (CLOV) has been subject to several lawsuits and federal investigations. Also, the company’s bottom line is in the red. However, CLOV is ramping up its efforts to accelerate its path to profitability. So, should you Buy, Hold or Sell the stock now? Read on to learn my views.

StockNews.com

The Clover Group buys Belfast bar the Eglantine Inn creating 30 new jobs and planning £500k refurbishment

The venue was first designed in 1988 by the same architects as the iconic Crown Bar

Belfast Live

Noted New Orleans social services group drops racist's name

A New Orleans social services nonprofit long known as the Kingsley House has ditched the name of a Victorian clergyman found to have held profoundly racist views

The Independent UK

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

RideApart

Clover Wants You To Stay Breezy With The Netstyle 2 Jacket

Italian gear and apparel maker Clover introduces the Netstyle 2 riding jacket for the 2022 season. This mesh jacket is meant to keep you cool this summer.

Bangkok Post

China's Clover says its Covid booster shot candidate lifts antibody against Omicron

BEIJING: China's Clover Biopharmaceuticals said on Monday a booster shot of its Covid-19 vaccine candidate significantly increased antibody response against the Omicron coronavirus variant from levels seen after two primary shots.

Bangkok Post

Victoria's Secret to pay B285m settlement to laid-off Thai workers

Thai workers who were sacked last year from a factory supplying global lingerie brands including Victoria's Secret will receive 285.2 million baht, in what labour activists say is the biggest settlement of its kind in the global garment industry.

Benzinga

How Clover Mortgage Is Helping Metro Detroiters Save On Homeownership As Rates Begin To Climb

Through the pandemic, Americans went on a homebuying spree. Amidst trends accelerated by work-from-home and pandemic isolation, families, some of which were first-time home buyers, drew on an already limited supply.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Clover Biopharmaceuticals Ltd announced new promising data from a preclinical study on its bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the omicron variant. Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus. It…

Benzinga

Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron

Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose. The follow-up analysis involved 26,400 individuals. Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated…

Benzinga

Why Did Chelsea Clinton Buy Shares Of This Healthcare Company?

Clover Health Investments Corp (NASDAQ: CLOV) shares are surging Monday following insider buying from a prominent public figure.

StockNews.com

Clover Health vs. Anthem: Which Healthcare Plan Stock is a Better Buy?

An aging population and rising healthcare spending have been driving the growth of the healthcare plans industry. Therefore, both Anthem (ANTM) and Clover (CLOV) should see an increase in demand for their products. But which one of these stocks is a better buy right now? Read on.

StockNews.com

Better Buy for 2022: Humana vs. Clover Health

The rising aging population and the increasing spending on healthcare have been driving the health insurance industry’s growth. So, Humana (HUM) and Clover (CLOV) should benefit. But which of these two stocks is a better buy now? Read more to find out.

Geekflare

16 Best Payment Processing Companies and Solutions

Explore the best payment processing services that offer secure, fast, and flexible transaction processing to enhance your business efficiency and customer experience.

TechRadar

I tested Clover - read what I thought of this point of sale system

Clover is a fitting point-of-sale system for small businesses, offering advanced features for an affordable price.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.